Single use daratumumab for AL amyloidosis
Daratumumab is a monoclonal antibody that binds to CD38, resulting in immune-mediated tumor cell death via apoptosis. Oliver Charles Cohen, MD, University College London Hospitals NHS Foundation Trust, London, UK, discusses rapid responses to single-agent daratumumab and the therapeutics association with improved progression-free survival in relapsed/refractory AL amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
